Mary Jane Minkin, MD, is codirector of the Sexuality, Intimacy & Menopause Program at Yale Medicine’s Smilow Cancer Hospital. She shares an encouraging message.
One day at the office, I developed a dull pain in my right lower abdomen that grew in intensity. I checked into the emergency room. My gallbladder was infected and had to come out. When I was in the ...
New York artist Pauline Decarmo transforms several bouts with cancer—and debilitating side effects—into paintings and a lifestyle that inspire.
Bone sarcoma, or primary bone cancer, originates in the bone tissue. It doesn’t include cancer that starts elsewhere in the body and spreads to the bones. Sarcomas also occur in soft connective ...
After a diagnosis of Stage IV prostate cancer, Euvon Jones turned his life around—with the help of his wife, Janet.
The American Cancer Society recommends between 150 and 320 minutes of yoga per week to speed recovery or defend against cancer occurrence or recurrence. (But, of course, you should speak with your ...
Families fighting childhood leukemia often battle another hardship: poverty. Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center show that one in three families of children ...
Patrons at bars and coffee shops in Georgia were spurred to talk about colon cancer thanks to a statewide awareness campaign called “Weird Looking Stools” that featured, well, exactly that. For the ...
While awareness of the role of physical activity in cancer survivors has increased, reducing sedentary behavior has been less emphasized. Studies indicate that cancer survivors with more sedentary ...
Leukemia and lymphoma are both blood cancers, but they have some distinct characteristics and different therapies. With advances in treatment, many people with these malignancies can be successfully ...
In September 2024, the FDA gave the nod to the first injectable checkpoint inhibitor, Tecentriq Hybreza, an injectable formulation of atezolizumab, soon followed by Opdivo Qvantig, an injectable ...
These results come on the heels of data presented at ASCO showing that another antibody-drug conjugate, Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan), improved progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback